MYL7
ENSG00000106631
Target class
Unclassified protein
Chromosome
7
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MYL7
- Gene name
- Myosin light chain 7
- Gene symbol
- MYL7
- Protein name
- Myosin regulatory light chain 2, atrial isoform (MLC-2a) (MLC2a) (Myosin light chain 2a) (Myosin regulatory light chain 7)
- MYLC2A
- MYL2A
- Gene biotype
- Protein coding
- Gene family
- Myosin light chains, class 2
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 19
- Highest tissue expression
- 7,135.04
- Tissue specificity (Gini)
- 0.975
- Tissue specificity (tau)
- 0.999
- KEGG gene identifiers
- hsa:58498
- Reactome pathways
- R-HSA-445355
- Protein interaction confidence
- 0.8119
- Protein interaction partners
- 30
- End position
- 44143179
- Start position
- 44138864
- Chromosome
- 7
- Strand
- Reverse
- Tissue specificity (tau)
- 0.998772
- Expression inequality (Gini)
- 0.975084
Expression in transcripts per million
- Heart - Atrial Appendage
- 7,135.04
- Heart - Left Ventricle
- 402.47
- Pituitary
- 12.97
- Brain - Cerebellar Hemisphere
- 3.62
- Brain - Cerebellum
- 3.61
Expression in transcripts per million
- Heart - Atrial Appendage7,135.04
- Heart - Left Ventricle402.47
- Pituitary12.97
- Brain - Cerebellar Hemisphere3.62
- Brain - Cerebellum3.61
- Brain - Hypothalamus3.55
- Artery - Coronary1.81
- Artery - Aorta1.73
- Brain - Cortex1.66
- Artery - Tibial1.55
- Brain - Nucleus accumbens (basal ganglia)1.4
- Uterus1.33
- Brain - Frontal Cortex (BA9)1.3
- Vagina1.26
- Breast - Mammary Tissue1.24
- Brain - Anterior cingulate cortex (BA24)1.17
- Nerve - Tibial1.14
- Cervix - Endocervix1.11
- Ovary1.09
- Brain - Amygdala0.98
- Esophagus - Gastroesophageal Junction0.95
- Fallopian Tube0.95
- Cervix - Ectocervix0.94
- Brain - Caudate (basal ganglia)0.94
- Brain - Spinal cord (cervical c-1)0.86
And 29 more, listed on the interactive page.
- GO:0005829
- GO:0031672
Molecular functions
- GO:0005515
Related records
Trials (65)
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
- A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- A Study of CK-1827452 Infusion in Stable Heart Failure
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
- A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
- A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
- A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Drugs (3)
- Danicamtiv Cardiac myosin activator
- Mavacamten Cardiac myosin inhibitor
- Omecamtiv mecarbil Cardiac myosin activator